Lv11
90 积分 2022-08-22 加入
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
1个月前
已完结
Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges
1个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
1个月前
已完结
Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion
7个月前
已完结
Selpercatinib Controls Central Nervous System Disease in Patients With NSCLC With RET Fusion
7个月前
已完结
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC
7个月前
已完结
Thymic Carcinoma With Malignant Effusion—a Rare Cytologic and Radiologic Mimicker of Metastatic NSCLC
7个月前
已完结
Alectinib in resected ALK-positive non-small-cell lung cancer
7个月前
已完结
皖公网安备34019202002308
